Trust Co. of Vermont Takes Position in Novo Nordisk A/S $NVO

Trust Co. of Vermont acquired a new position in shares of Novo Nordisk A/S (NYSE:NVO) in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 26,069 shares of the company’s stock, valued at approximately $1,250,000.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Loomis Sayles & Co. L P raised its stake in Novo Nordisk A/S by 6.0% during the 4th quarter. Loomis Sayles & Co. L P now owns 17,135,384 shares of the company’s stock valued at $871,848,000 after acquiring an additional 969,916 shares in the last quarter. Franklin Resources Inc. increased its holdings in shares of Novo Nordisk A/S by 5.1% during the fourth quarter. Franklin Resources Inc. now owns 14,702,508 shares of the company’s stock valued at $748,064,000 after purchasing an additional 717,719 shares during the period. Morgan Stanley increased its holdings in shares of Novo Nordisk A/S by 3.5% during the fourth quarter. Morgan Stanley now owns 12,842,089 shares of the company’s stock valued at $653,406,000 after purchasing an additional 428,660 shares during the period. Price T Rowe Associates Inc. MD raised its stake in shares of Novo Nordisk A/S by 99.7% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 9,688,262 shares of the company’s stock valued at $492,940,000 after purchasing an additional 4,836,285 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership bought a new stake in shares of Novo Nordisk A/S during the first quarter valued at about $287,660,000. 11.54% of the stock is owned by institutional investors.

Novo Nordisk A/S Price Performance

Shares of Novo Nordisk A/S stock opened at $45.71 on Wednesday. The company has a current ratio of 0.79, a quick ratio of 0.56 and a debt-to-equity ratio of 0.59. The company’s 50-day moving average price is $47.51 and its two-hundred day moving average price is $44.15. Novo Nordisk A/S has a 52 week low of $35.12 and a 52 week high of $64.16. The stock has a market cap of $204.10 billion, a PE ratio of 11.18, a price-to-earnings-growth ratio of 4.15 and a beta of 0.76.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings results on Tuesday, June 30th. The company reported $0.94 earnings per share for the quarter. Novo Nordisk A/S had a net margin of 35.36% and a return on equity of 61.20%. The company had revenue of $11.98 billion during the quarter. As a group, sell-side analysts anticipate that Novo Nordisk A/S will post 3.41 EPS for the current fiscal year.

Novo Nordisk A/S Cuts Dividend

The firm also recently announced a dividend, which will be paid on Tuesday, August 25th. Investors of record on Monday, August 17th will be paid a dividend of $0.5786 per share. The ex-dividend date of this dividend is Monday, August 17th. This represents a yield of 258.0%. Novo Nordisk A/S’s dividend payout ratio is currently 42.79%.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on NVO shares. Berenberg Bank set a $47.00 target price on shares of Novo Nordisk A/S in a research report on Wednesday, August 12th. Citigroup reaffirmed a “neutral” rating on shares of Novo Nordisk A/S in a research note on Monday, July 20th. Weiss Ratings upgraded shares of Novo Nordisk A/S from a “sell (d+)” rating to a “hold (c-)” rating in a report on Wednesday, August 5th. HSBC reiterated a “hold” rating on shares of Novo Nordisk A/S in a research note on Monday, July 6th. Finally, Zacks Research upgraded Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a research report on Tuesday, August 11th. Four analysts have rated the stock with a Buy rating and sixteen have issued a Hold rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $64.94.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.